A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01889186
• Other study ID #: M13-982
• Secondary ID: 2012-004027-20
• Status: Completed
• Phase: Phase 2
• Start date: June 27, 2013
• Est. completion date: December 15, 2020

Study information

• Verified date: November 2021
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring 17p deletion.

Description:

This study was designed to enroll approximately 150 participants in 2 cohorts: a main cohort of approximately 100 participants, and a safety expansion (SE) cohort of approximately 50 participants. The primary objective of the main cohort was to evaluate the efficacy of ABT-199 monotherapy in participants with R/R CLL harboring the 17p deletion. The primary objective of the safety expansion cohort was to evaluate the safety of ABT-199 in approximately 50 participants with R/R CLL harboring 17p deletion treated per updated tumor lysis syndrome (TLS) prophylaxis and management measures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 158
• Est. completion date: December 15, 2020
• Est. primary completion date: October 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Participant must be greater than or equal to 18 years of age.

• Participant must have diagnosis of chronic lymphocytic leukemia (CLL) that meets published 2008 Modified IWCLL NCI-WG (International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group) Guidelines.

• Participant has an indication for treatment according to the 2008 Modified IWCLL NCI WG Guidelines;

• Participant has clinically measurable disease (lymphocytosis > 5 × 10^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam);

• Participant must be refractory or have relapsed after receiving at least one prior line of therapy (participants that have progressed after 1 cycle of treatment or have completed at least 2 cycles of treatment for a given line of therapy) or previously untreated CLL (previously untreated CLL participants must have received no prior chemotherapy or immunotherapy. Participants with a history of emergency, loco-regional radiotherapy (e.g., for relief of compressive signs or symptoms) are eligible. In addition, participants must meet the CLL diagnostic criteria above and must have > 5 × 10^9/L B-Lymphocytes in the peripheral blood.);

• Participants must have 17p deletion, assessed by local laboratory (in bone marrow or peripheral blood) or assessed by central laboratory (peripheral blood).

• Participant has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.

• Participant must have adequate bone marrow function at Screening as follows:

• Absolute Neutrophil Count (ANC) greater than or equal to 1000/µL, or

• For subjects with an ANC less than 1000/µL at Screening and bone marrow heavily infiltrated with underlying disease (unless cytopenia is clearly due to marrow involvement of CLL), growth factor support may be administered after Screening and prior to the first dose of ABT-199 to achieve the ANC eligibility criteria (greater than or equal to 1000/µL);

• Platelets greater than 30,000/mm^3 (without transfusion support within 14 days of Screening, without evidence of mucosal bleeding, without known history of bleeding episode within 3 months of Screening, and without history of bleeding disorder);

• Hemoglobin greater than or equal to 8.0 g/dL.

• Participant must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening as follows:

• Activated partial thromboplastin time (aPTT) and prothrombin time (PT) not to exceed 1.5 × the upper limit of normal;

• Calculated creatinine clearance greater than 50 mL/min using 24-hour Creatinine Clearance or modified Cockcroft-Gault equation (using Ideal Body Mass [IBM] instead of Mass). For participants that have body mass index (BMI) of > 30 kg/m^2 or < 19 kg/m^2, 24-hour measured urine creatinine clearance is required;

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3.0 × the upper normal limit of institution's normal range; Bilirubin less than or equal to 1.5 × upper limit of normal. Participants with Gilbert's Syndrome may have a bilirubin greater 1.5 × upper limit of normal, per correspondence between the investigator and AbbVie medical monitor.

• For participants at high risk of tumor lysis syndrome a pre-approval by the AbbVie medical monitor is required prior to enrollment.

Exclusion Criteria:

• Participant has undergone an allogeneic stem cell transplant.

• Participant has developed Richter's transformation confirmed by biopsy.

• Participant has prolymphocytic leukemia.

• Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose corticosteroids.

• Participant has previously received ABT-199.

• Participant has received a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug.

• Participant has received any of the following within 14 days or 5 half-lives as applicable prior to the first dose of study drug, or has not recovered to less than Common Toxicity Criteria (CTC) grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy:

• Any anti-cancer therapy including chemotherapy, or radiotherapy;

• Investigational therapy, including targeted small molecule agents.

• Participant has known allergy to both xanthine oxidase inhibitors and rasburicase.

Related Conditions & MeSH terms

• Cancer of the Blood and Bone Marrow
• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• ABT-199 (Main Cohort)
Participants received a test dose of ABT-199 of = 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: ? 100 mg ? 200 mg ? 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
• ABT-199 (Safety Expansion Cohort)
Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg ? 200 mg ? 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.

Locations

Country	Name	City	State
Australia	John Fawkner Private Hospital /ID# 98835	Coburg	Victoria
Australia	Peter MacCallum Cancer Ctr /ID# 91795	Melbourne	Victoria
Australia	Royal Melbourne Hospital /ID# 91794	Parkville	Victoria
Australia	Royal North Shore Hospital /ID# 98836	St Leonards	New South Wales
Canada	Duplicate_Jewish General Hospital /ID# 99476	Montreal	Quebec
France	Hopital Avicenne - APHP /ID# 98840	Bobigny	Ile-de-France
France	Hopital Pitie Salpetriere /ID# 98842	Paris
France	Centre Hospitalier Lyon Sud /ID# 98839	Pierre Benite CEDEX	Auvergne-Rhone-Alpes
France	Centre Henri Becquerel /ID# 98838	Rouen
Germany	Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 113256	Dresden
Germany	Universitaetsklinikum Freiburg /ID# 113276	Freiburg
Germany	Universitaetsmedizin Goettingen /ID# 113258	Göttingen
Germany	Universitaetsklinik Heidelberg /ID# 98845	Heidelberg	Baden-Wuerttemberg
Germany	Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 113235	Kiel	Schleswig-Holstein
Germany	Uniklinik Koeln /ID# 98847	Köln	Nordrhein-Westfalen
Germany	Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 113236	Mainz
Germany	Muenchen Klinik Schwabing /ID# 113275	Muenchen
Germany	Universitaetsklinikum Ulm /ID# 92533	Ulm	Thueringen
Poland	SP ZOZ Szpital Uniwersytecki w Krakowie /ID# 98849	Krakow	Malopolskie
Poland	Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie /ID# 98848	Lublin	Lubelskie
Poland	Szpital Wojewodzki w Opolu /ID# 102855	Opole	Opolskie
United Kingdom	The Royal Bournemouth Hospital /ID# 118975	Bournemouth
United Kingdom	Addenbrookes Hospital /ID# 119977	Cambridge
United Kingdom	St. James University Hospital /ID# 98863	Leeds
United Kingdom	Leicester Royal Infirmary /ID# 98865	Leicester	England
United Kingdom	Royal Liverpool and Broadgreen /ID# 98860	Liverpool
United Kingdom	King's College Hospital NHS Foundation Trust /ID# 119975	London
United Kingdom	St Bartholomew's Hospital, Bar /ID# 98862	London
United Kingdom	The Christie Hospital /ID# 98864	Manchester
United Kingdom	Oxford Univ Hosp NHS Trust /ID# 119976	Oxford
United Kingdom	Derriford Hospital /ID# 118335	Plymouth
United Kingdom	Royal Marsden Hospital /ID# 98861	Sutton
United States	Dana-Farber Cancer Institute /ID# 92494	Boston	Massachusetts
United States	Northwestern University Feinberg School of Medicine /ID# 92499	Chicago	Illinois
United States	The University of Chicago Medical Center /ID# 96960	Chicago	Illinois
United States	Cleveland Clinic Main Campus /ID# 92495	Cleveland	Ohio
United States	Henry Ford Health System /ID# 97795	Detroit	Michigan
United States	City of Hope /ID# 112875	Duarte	California
United States	Hackensack Univ Med Ctr /ID# 92500	Hackensack	New Jersey
United States	Ingalls Memorial Hosp /ID# 92497	Harvey	Illinois
United States	University of Texas MD Anderson Cancer Center /ID# 92521	Houston	Texas
United States	Moore UC San Diego Cancer Center /ID# 91793	La Jolla	California
United States	Rutgers Cancer Institute of New Jersey /ID# 92513	New Brunswick	New Jersey
United States	Columbia Univ Medical Center /ID# 103835	New York	New York
United States	Columbia Univ Medical Center /ID# 94716	New York	New York
United States	Stanford University School of Med /ID# 105117	Stanford	California
United States	University of Arizona Cancer Center - North Campus /ID# 96748	Tucson	Arizona
United States	Georgetown University Hospital /ID# 96954	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie	Genentech, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Germany,  Poland,  United Kingdom, 

References & Publications (1)

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (Main Cohort)	The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission [CR] + complete remission with incomplete marrow recovery [CRi] + nodular partial remission [nPR] + partial remission [PR]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria as assessed by the Independent Review Committee (IRC) in the first 70 participants treated in the Main Cohort.	Up to 36 weeks
Primary	Number of Participants With Adverse Events (Safety Expansion Cohort)	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.	From the first dose of study drug until 30 days following last dose of study drug (up to 69 months)
Secondary	Overall Response Rate (ORR) (Safety Expansion Cohort)	The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission [CR] + complete remission with incomplete marrow recovery [CRi] + nodular partial remission [nPR] + partial remission [PR]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Complete Remission (CR) Rate	Complete remission was defined as the proportion of participants who achieved a CR or Complete Remission with Incomplete Marrow Recovery(CRi ) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a CR or CRi were considered to be non-responders in the calculation of CR rate.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Partial Remission (PR) Rate	PR rate was defined as the proportion of participants who achieved a nodular partial remission (nPR) or PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a nPR or PR were considered to be non-responders in the calculation of PR rate.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Duration of Overall Response	Duration of overall response (DoR) was defined as the number of days from the date of first response (CR, CRi, nPR, or PR) by either CT scan or physical exam determination to the earliest recurrence (progressive disease; PD) or death. For participants who had a PR before CR, CRi, or nPR in subsequent visits, the DoR was computed from the earliest PR. If a participant was still responding, then their data was censored at the date of their last available disease assessment. To be included in the DoR analysis, participants must have had a response per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria (CR, CRi, confirmed nPR, or confirmed PR). For participants who never experienced response, their data was not included in the analysis.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Progression-free Survival	Duration of progression-free survival (PFS) was defined as the number of days from the date of first dose to the date of earliest disease progression or death. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant does not experience disease progression or death, then the data was censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Event-free Survival	Event-free survival (EFS) was defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy. If the specified event (disease progression, death, start of a new anti-leukemic treatment) did not occur, participants were censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Time to Progression	Time to progression (TTP) was defined as the number of days from the date of first dose to the date of earliest disease progression. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant did not experience disease progression, then the data was censored at the date of last available disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Time to First Response	Time to first response was defined as the number of days from the date of first dose to the date of the first sign of response (CR, CRi, nPR, or PR) given the participant has had a CR, CRi, confirmed nPR, or confirmed PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. The first response could have been an assessment by physical exam as long as the results were later confirmed per the 2008 Modified IWCLL NCI-WG criteria. For participants who never experienced a response, the participant's data were not included in the analysis.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Time to 50% Reduction in Absolute Lymphocyte Count	Time to 50% reduction in absolute lymphocyte count (ALC) was defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC had reduced to 50% of the baseline value. Only participants with a baseline of ALC > 5 × 10^9 /L were included in the analysis. For participants who never achieved a 50% reduction in ALC, the participant's data were not included in the analysis.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Secondary	Overall Survival	Overall survival (OS) was defined as number of days from the date of first dose to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later.	Up to the data cutoff date of 15 December 2020, approximately 7.5 years of follow-up
Secondary	Percentage of Participants Who Moved on to Stem Cell Transplant	The percentage of participants who moved on to stem cell transplant was summarized.	Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up